You are here

Article Text

Article menu
Download PDFPDF
Aetiology
Cohort study
Ranitidine use is associated with increased morbidity and mortality in very low birthweight infants
  1. C Michael Cotten,
  2. William F Malcolm
  1. Department of Pediatrics-Neonatology, Duke University, Durham, North Carolina, USA
  1. Correspondence to: C Michael Cotten
    Pediatrics-Neonatology, Duke University, 2424 Erwin Road suite 504, Durham, NC 27705, USA; cotte010{at}mc.duke.edu

https://doi.org/10.1136/ebmed-2012-100622

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Terrin G, Passariello A, De Curtis M, et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics 2012;129:e40–5.OpenUrlAbstract/FREE Full Text

    Context

    Gastroesophageal reflux (GER) is the retrograde movement of stomach contents into the oesophagus. Pharmacotherapy aimed at reducing problems attributed to GER includes histamine receptor blockers (H2 blockers), such as ranitidine, which reduce stomach acidity. Extremely preterm infants often exhibit clinical signs consistent with GER,1 and GER medications are among the most commonly prescribed medications in neonatal intensive care units (NICUs).2

    Approximately one third of extremely premature (<28 weeks gestation), very low birthweight (VLBW; <1500 g) infants acquire infections during their NICU stay. Necrotising enterocolitis (NEC), a serious intestinal morbidity in preterm infants, occurs in approximately 10%. About half …

    View Full Text

    Footnotes

    • Competing interests WFM has received funding from the Gerber Foundation for studies of gastroesophageal reflux. CMC has no conflicting interests.